ucb-34714 and Dystonia

ucb-34714 has been researched along with Dystonia* in 1 studies

Other Studies

1 other study(ies) available for ucb-34714 and Dystonia

Article	Year
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster. European journal of pharmacology, 2008, Dec-28, Volume: 601, Issue:1-3 Previous examinations demonstrated antidystonic effects of the synaptic vesicle protein 2A (SV2A) ligand levetiracetam in the dt(sz) mutant hamster, an animal model of paroxysmal non-kinesiogenic dyskinesia in which dystonic episodes can be induced by stress. In the present study, we examined the effects of the two new, high affinity SV2A ligands, brivaracetam and seletracetam, in comparison to levetiracetam on the severity of dystonia in mutant hamsters. Seletracetam (50 and 75 mg/kg i.p.) and brivaracetam (75 mg/kg i.p.) reduced the severity of dystonia to a comparable extent as levetiracetam (50 and 75 mg/kg i.p.). These data confirm the therapeutic potential of these pyrrolidone derivatives for the treatment of paroxysmal dystonia. Topics: Animals; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dystonia; Humans; Levetiracetam; Ligands; Membrane Glycoproteins; Nerve Tissue Proteins; Piracetam; Pyrrolidinones; Severity of Illness Index	2008

Article

Year

Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster.

European journal of pharmacology, 2008, Dec-28, Volume: 601, Issue:1-3

Previous examinations demonstrated antidystonic effects of the synaptic vesicle protein 2A (SV2A) ligand levetiracetam in the dt(sz) mutant hamster, an animal model of paroxysmal non-kinesiogenic dyskinesia in which dystonic episodes can be induced by stress. In the present study, we examined the effects of the two new, high affinity SV2A ligands, brivaracetam and seletracetam, in comparison to levetiracetam on the severity of dystonia in mutant hamsters. Seletracetam (50 and 75 mg/kg i.p.) and brivaracetam (75 mg/kg i.p.) reduced the severity of dystonia to a comparable extent as levetiracetam (50 and 75 mg/kg i.p.). These data confirm the therapeutic potential of these pyrrolidone derivatives for the treatment of paroxysmal dystonia.

Topics: Animals; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Dystonia; Humans; Levetiracetam; Ligands; Membrane Glycoproteins; Nerve Tissue Proteins; Piracetam; Pyrrolidinones; Severity of Illness Index

2008